DNA vaccines for cervical cancer

American Journal of Translational Research

Volumn 2, Issue 1, 2010, Pages 75-87

  Huang, Chien Fu ^a   Monie, Archana ^a   Weng, Wei Hung ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cervical cancer; DNA vaccines; Human papillomavirus

Indexed keywords

DNA VACCINE; PLACEBO; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ZYC 101;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG POTENCY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 77953377792     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
5. Roden R and Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6: 753-763.
6. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
7. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E and Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
8. Harper DM. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 2008; 110: S11-17.
9. Crook T, Morgenstern JP, Crawford L and Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. Embo J 1989; 8: 513-519.
10. Donnelly JJ, Ulmer JB, Shiver JW and Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648.
11. Gurunathan S, Klinman DM and Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-974.
12. Guermonprez P, Valladeau J, Zitvogel L, Thery C and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667.
13. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
14. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
15. Payne LG, Fuller DH and Haynes JR. Particlemediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Curr Opin Mol Ther 2002; 4: 459-466.
16. Condon C, Watkins SC, Celluzzi CM, Thompson K and Falo LD, Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-1128.
17. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP and Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075-1082.
18. Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF and Wu TC. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 2008; 15: 1156-1166.
19. Chen CA, Chang MC, Sun WZ, Chen YL, Chiang YC, Hsieh CY, Chen SM, Hsiao PN and Cheng WF. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects. Gene Ther 2009; 16: 776-787.
20. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D and Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26: 5210-5215.
21. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB and Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27: 431-440.
22. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC and Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009;
23. Cheng JY, Huang HN, Tseng WC, Li TL, Chan YL, Cheng KC and Wu CJ. Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection. J Control Release 2009; 135: 242-249.
24. Zeira E, Manevitch A, Manevitch Z, Kedar E, Gropp M, Daudi N, Barsuk R, Harati M, Yotvat H, Troilo PJ, Griffiths TG, 2nd, Pacchione SJ, Roden DF, Niu Z, Nussbaum O, Zamir G, Papo O, Hemo I, Lewis A and Galun E. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J 2007; 21: 3522-3533.
25. Hung C-F, Cheng W-F, Chai C-Y, Hsu K-F, He L, Ling M and Wu T-C. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-5740.
26. Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA and Wu TC. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004; 15: 167-177.
27. Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF and Wu TC. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 2005; 12: 689-700.
28. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin KQ and Okuda K. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006; 354: 48-57.
29. Lundberg M and Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol 2001; 19: 713-714.
30. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L and Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21: 4036-4042.
31. Hauser H and Chen SY. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 2003; 31: 225-231.
32. Hauser H, Shen L, Gu QL, Krueger S and Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004; 11: 924-932.
33. Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC, Hsieh CY and Cheng WF. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol 2007; 107: 404-412.
34. Hung C-F, Hsu K-F, Cheng W-F, Chai C-Y, He L, Ling M and Wu T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Flt3-ligand. Cancer Research 2001; 61: 1080-1088.
35. Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW and Wu TC. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007; 67: 802-811.
36. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, Chuang CM, Lin CT, Tsai YC, He L, Monie A and Wu TC. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008; 14: 3185-3192.
37. Tseng CW, Monie A, Wu CY, Huang B, Wang MC, Hung CF and Wu TC. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med 2008; 86: 899-908.
38. Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, Straughn JM, Jr., Wang MC, Yagita H, Hung CF and Wu TC. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008; 26: 4314-4319.
39. Chuang CM, Monie A, Wu A and Hung CF. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci 2009; 16: 49.
40. Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF and Lai CH. A DNA Vaccine Encoding a Codon-Optimized Human Papillomavirus Type 16 E6 Gene Enhances CTL Response and Anti-tumor Activity. J Biomed Sci 2006;
41. Brinkman JA, Xu X and Kast WM. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 2007; 25: 3437-3444.
42. Lu D, Hoory T, Monie A, Wu A, Wang MC and Hung CF. Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009; 27: 4363-4369.
43. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM and Wu T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Research 2000; 60: 1035-1042.
44. Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT and Wu TC. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003; 63: 2393-2398.
45. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M and Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-678.
46. Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R and Wu TC. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26: 351-360.
47. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF and Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004; 78: 8468-8476.
48. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA and Wu TC. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11: 1011-1018.
49. Hung C-F, Cheng W-F, Hsu K-F, Chai C-Y, He L, Ling M and Wu T-C. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Research 2001; 61: 3698-3703.
50. Castellino F and Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 2006; 24: 519-540.
51. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August T and Pardoll DM. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. 1995; 92: 11671-11675.
52. Ji H, Wang T-L, Chen C-H, Hung C-F, Pai S, Lin KY, Kurman RJ, Pardoll DM and Wu T-C. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 1999; 10: 2727-2740.
53. Kim D, Hoory T, Monie A, Ting JP, Hung CF and Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008; 180: 7019-7027.
54. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC and Hung CF. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005; 12: 1180-1186.
55. Hung CF, Calizo R, Tsai YC, He L and Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007; 25: 127-135.
56. Lin CT, Tsai YC, He L, Yeh CN, Chang TC, Soong YK, Monie A, Hung CF and Lai CH. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 2007; 114: 86-93.
57. Hsieh CY, Chen CA, Huang CY, Chang MC, Lee CN, Su YN and Cheng WF. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 2007; 15: 1890-1897.
58. Ohlschlager P, Quetting M, Alvarez G, Durst M, Gissmann L and Kaufmann AM. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 2009; 125: 189-198.
59. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF and Wu TC. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65: 309-316.
60. Huang B, Mao CP, Peng S, Hung CF and Wu TC. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19: 763-773.
61. Kim D, Hoory T, Wu TC and Hung CF. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther 2007; 18: 1129-1139.
62. Huang B, Mao CP, Peng S, He L, Hung CF and Wu TC. Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 2007; 25: 7824-7831.
63. Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, Su YN, Hsieh CY and Chen CA. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther 2008; 15: 1007-1016.
64. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994; 12: 259-293.
65. Trombetta ES and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028.
66. Hung CF, Tsai YC, He L and Wu TC. DNA Vaccines Encoding Ii-PADRE Generates Potent PADREspecific CD4(+) T-Cell Immune Responses and Enhances Vaccine Potency. Mol Ther 2007; 15: 1211-1219.
67. Kim D, Monie A, He L, Tsai YC, Hung CF and Wu TC. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ Tcell immune responses. Gene Ther 2008; 15: 677-687.
68. Chuang CM, Hoory T, Monie A, Wu A, Wang MC and Hung CF. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine 2009; 27: 684-689.
69. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA and Crowley-Nowick PA. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188: 916-926.
70. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M and Palefsky JM. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002; 8: 1028-1037.
71. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML and Beach KJ. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103: 317-326.
72. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D and Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15: 361-367.
73. Chen CH, Wang TL, Hung CF, Pardoll DM and Wu TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000; 18: 2015-2022.
74. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K and Inglis SC. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996; 14: 1485-1494.
75. Stary G, Bangert C, Tauber M, Strohal R, Kopp T and Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-1451.
76. Peggs KS, Quezada SA, Korman AJ and Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
77. Blank C and Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-745.
78. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW, Jr., Chen L, Pardoll DM and Drake CG. Role of PD -1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007; 110: 186-192.
79. Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
80. Groh V, Wu J, Yee C and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
81. Munn DH and Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004; 10: 15-18.
82. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL and Rabinovich GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumorimmune privilege. Cancer Cell 2004; 5: 241-251.
83. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S and Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630-637.
84. Gorelik L and Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118-1122.
85. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
86. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-835.